




RealRate

PHARMACEUTICAL 2026

Moonlake Immunotherapeutics
Rank 63 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Moonlake Immunotherapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moonlake Immunotherapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Moonlake Immunotherapeutics is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 45% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	421,694
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	45,478
Liabilities, Non-Current	74,474
Other Assets	2,162
Other Compr. Net Income	-1,409
Other Expenses	7,859
Other Liabilities	0
Other Net Income	0
Other Revenues	22,372
Property and Equipment	577
Research and Development	202,862
Selling, General and Administrative Expense	41,972

Output Variable	Value in 1000 USD
Assets	424,433
Liabilities	119,952
Expenses	252,693
Revenues	22,372
Stockholders Equity	304,481
Net Income	-230,321
Comprehensive Net Income	-231,026
BaseVar	410,430
ECR before LimitedLiability	159%
Economic Capital Ratio	274%